Peptech Limited Appoints Chief Medical Officer In Preparation for Advancing to Phase II Patient Trials

Published: Jun 05, 2007

Sydney, 6 June 2007: Peptech Limited (ASX: PTD, AIM: PTDx) today announced the appointment of Dr. David Fuller as Chief Medical Officer. The appointment is a crucial step in Peptech’s plans to rapidly advance the clinical trial program of its lead anti-inflammatory compound, PN0621.

Back to news